The Phase I Program oversees research dedicated to studying new drugs that may become effective treatments for cancer. Our program introduces new drugs and drug combinations to patients who have demonstrated disease or metastatic progression on existing treatments and have no clear therapeutic options with significant benefits. We conduct phase I clinical trials that are carefully designed safety studies of experimental drugs being given to patients for the first time.
Through our program, patients who respond to treatment in clinical trials and those who do not respond will have repeat biopsies performed whenever possible. We perform whole genome sequencing and RNA expression analysis on each sample, including your original diagnostic tumor biopsy. This way, information from these biopsies will be available to you and your physician when it comes time to make the next treatment decision.
Our program offers clinical trials for patients in need of phase I therapy options from all 13 of the clinical disease programs within Yale Cancer Center.